CLOSE

Specials

I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

Skip to: Curated Story Group 1
lifesciencesreview
US
EUROPE
APAC
CANADA
  • US
    • US
    • EUROPE
    • APAC
    • CANADA
    • LATAM
  • Home
  • Contributors
  • News
  • Conferences
  • Newsletter
  • Whitepapers
  • Magazine
×
#

Life Science Review Weekly Brief

Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Life Science Review

Subscribe

loading

Thank you for Subscribing to Life Science Review Weekly Brief

  • Home
  • News

Recommended picks

Analysis of Bioanalytical Services Market

Analysis of Bioanalytical Services...

Trudiagnostic Unveils Truage PACE For Tracking Biological Aging Rate

Trudiagnostic Unveils Truage PACE For...

Know More About the Comprehensive Bioanalytical Testing Services

Know More About the Comprehensive...

Ways Bioanalytical Laboratory Automation Boosts Efficiency and Accuracy

Ways Bioanalytical Laboratory...

Analytics' Role in Pharmaceutical Success

Analytics' Role in Pharmaceutical...

Discovering and developing drugs using bioanalysis

Discovering and developing drugs...

Developing Next-Generation Technologies for a Better Tomorrow

Developing Next-Generation...

Why Outsource Bioanalysis Work?

Why Outsource Bioanalysis Work?

Analysis of Bioanalytical Services Market

Analysis of Bioanalytical Services...

Trudiagnostic Unveils Truage PACE For Tracking Biological Aging Rate

Trudiagnostic Unveils Truage PACE For...

Know More About the Comprehensive Bioanalytical Testing Services

Know More About the Comprehensive...

Ways Bioanalytical Laboratory Automation Boosts Efficiency and Accuracy

Ways Bioanalytical Laboratory...

Analytics' Role in Pharmaceutical Success

Analytics' Role in Pharmaceutical...

Discovering and developing drugs using bioanalysis

Discovering and developing drugs...

Developing Next-Generation Technologies for a Better Tomorrow

Developing Next-Generation...

Why Outsource Bioanalysis Work?

Why Outsource Bioanalysis Work?

BioStem Technologies Announces the Approval of Q Code for VENDAJE from CMS

Life Sciences Review Life Sciences Review | Tuesday, July 27, 2021
Tweet

BioStem Technologies announces that the CMS had released a new code in response to the Company's application for Healthcare Common Procedure Coding System (HCPCS) Q codes.


FREMONT, CA: BioStem Technologies, Inc., a preclinical-stage biotechnology firm prioritizing on leveraging perinatal tissue elements for use in regenerative therapies, announces that the Centers for Medicare and Medicaid Services (CMS) had released a new code in response to the Company's application for Healthcare Common Procedure Coding System (HCPCS) Q codes. The Company first requested that CMS create a new HCPCS Q code for VENDAJE in July 2020 and has now achieved a favorable judgment in July of 2021.


VENDAJE's HCPCS Q-code will be billed as Q4252, and it will become effective from October 1st, 2021. Q-Codes were created to identify drugs, biologicals, medical devices, and services that were not recognized by national HCPCS Level II codes yet required for Medicare claims processing. The HCPCS Committee, a subcommittee of CMS, allocates Q-Codes depending on the Committee's review. The HCPCS national panel manages them, which includes representatives from the Health Insurance Association of America, Blue Cross/Blue Shield, and CMS,


Jason Matuszewski, CEO of BioStem Technologies, states, "Establishment of a unique Q-code for VENDAJE is an integral building block to our growth and reimbursement strategy and will offer greater access to our tissue allografts for patients and providers through Medicare and the CMS system. We are excited about the opportunities that this new Q-code provides for our customers to now more appropriately bill and code for VENDAJE and we anticipate significant growth opportunities. We will continue to work to ensure we can deliver better outcomes that improve quality of life, reduce recovery times, and lower costs."


BioStem Technologies, Inc. is a preclinical biotechnology business that aims to use perinatal tissue and the body's intrinsic biology to heal or reverse the damage created by various degenerative diseases. Local Microenvironment Activation, or LMA, is their patented technology that utilizes a combination of small molecules, cytokines, and growth factors to awaken the microenvironment inside the body and establish communication for tissue repair.


Weekly Brief

loading
> <
  • Clinical Lab Equipment 2023

    Top Vendors

    Current Issue
  • Proteomics 2022

    Top Vendors

    Current Issue
  • Clinical Lab Equipment 2023

    Top Vendors

    Current Issue
  • Proteomics 2022

    Top Vendors

    Current Issue

Read Also

Qualities to Consider when Choosing Life Sciences Business Consultants for Your Firm

How Biotech Startups can Mitigate Risks in Order to Grow Sustainably

Cellf BIO's BioShincter to Undergo Phase 1 Trail to Test Fecal Incontinence Treatment

Fulcrum Therapeutics Announces CEO Transition

An Overview of Wholesalers' Roles in Complex Supply Chains

Veeva Opening Up Integration Module for Future Opportunities and Applications

Veeva Systems To Accelerate the CRM of Life Science Businesses

The Role of Technology in Advancing Clinical Trials

Loading...

Copyright © 2023 Life Sciences Review . All rights reserved. |  Subscribe |  About Us follow on linkedin

This content is copyright protected

However, if you would like to share the information in this article, you may use the link below:

https://www.lifesciencesreview.com/news/biostem-technologies-announces-the-approval-of-q-code-for-vendaje-from-cms-nwid-468.html